Long-term treatment with esketamine nasal spray in patients with treatment resistant depression: Results from the ESCAPE-LTE study.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology June 1, 2026 A Reif, Yağcıoğlu Ae Anıl, I Bitter et al. 3 citations
A 2-year extension of a clinical trial followed 183 adults with treatment-resistant depression who had been using esketamine nasal spray alongside an antidepressant. Over 136 weeks, 96.7% reported side effects, but 98.3% of those occurring on dosing days resolved the same day, and only 3.3% stopped treatment due to side effects. Among patients who achieved remission during the earlier phase, 79.2% did not relapse or discontinue treatment throughout the extension; the overall relapse rate for those reaching remission across both studies was 6.9%. No new safety concerns emerged, and the safety profile matched that seen in shorter-term studies.